CoChat
Sign Up
Cited by 73HIV/AIDS oral health manifestationsAntifungal resistance and susceptibilityNail Diseases and Treatments

Oral candidiasis and seborrheic dermatitis in HIV‐infected patients on highly active antiretroviral therapy

Open access
Dunic, I, Vesic, S, Jevtovic, DJ·2004·HIV Medicine
DOI 10.1111/j.1468-1293.2004.00185.x
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Mucocutaneous manifestations such as oral candidiasis (OC) and seborrheic dermatitis (SD) are very common HIV-related opportunistic events and are usually initial markers of immunodeficiency. AIM: The purpose of this study was to evaluate the efficacy of highly active antiretroviral therapy (HAART) in the regression of HIV-associated OC and SD. METHODS: In a prospective study, 120 HIV-infected patients with OC and SD were divided into two groups: HAART-treated patients (group 1, n=76) and non-HAART-treated patients (group 2, n=44). Non-HAART-treated patients were given antimicrobial therapy. Study subjects were matched for sex, age, risk, and stage of HIV infection. The results were analysed by chi2 test and the Kaplan-Meier method. RESULTS: At baseline, OC was evident in 59 (77.7%) of the HAART-treated patients and in 34 (77.3%) of the non-HAART-treated patients, while SD was present in 19 (25.0%) of the HAART-treated patients and in 17 (38.6%) of the non-HAART-treated patients. After a median follow-up period of 22 months, regression of OC and SD occurred in 49 (83.1%) and 16 (84.2%) of the HAART-treated patients, respectively. In the control group, regression of OC and SD occurred in only five (14.7%) and seven (41.2%) patients, respectively, during the same period. CONCLUSIONS: HAART showed greater efficacy than standard antimicrobial therapy for the treatment of OC and SD in HIV-infected patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1468-1293.2004.00185.x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The incidence of SD among HIV patients ranges from 30% to 83%.

    “The incidence among HIV patients ranges from 30% to 83% [9,10].”

    From Seborrheic Dermatitis and Dandruff: A Comprehensive Review (2015) · cites this paper as [10]

    The Introduction (page not provided) gives SD prevalence among HIV-infected persons as 7–50%, not an incidence range of 30–83%. The paper reports a different measure and a contrary numerical range. (LLM, conf=0.88)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

  • SD is more prevalent in immune-compromised patients such as HIV/AIDS patients, organ transplant recipients, and patients with lymphoma.

    “SD is more prevalent in immune-compromised patients such as HIV/AIDS patients [7,10], organ transplant recipients [11,12], and patients with lymphoma [13].”

    From Seborrheic Dermatitis and Dandruff: A Comprehensive Review (2015) · cites this paper as [10]

  • There have been reports of SD regression with HAART.

    “However, there have also been reports of SD regression with HAART [10].”

    From Seborrheic Dermatitis and Dandruff: A Comprehensive Review (2015) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 22

  1. 1 Johnson RA Cutaneous manifestations of human immunodeficiency virus disease, In: Freedberg IM, Eisen AZ, Wolf K, eds. Fitzpatrick's Dermatology in General Medicine, 5th edn. New York, McGraw-Hill 1999: 2505-2538.
  2. Munoz-Perez MA, Rodriguez-Pichardo A, Camacho F, Colmenero MA. Dermatological finding correlated with CD4 lymphocyte count in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br J Dermatol 1998; 139: 33-39.
  3. Schaub N, Gilli L, Rufli T. Epidemiology of skin diseases in HIV-infected patients: a prospective cohort study. Schweiz Rundsch Med Prax 1996; 17: 1162-1166.
  4. Patton LL, van der Horst C. Oral infections and other manifestations of HIV disease. Infect Dis Clin North Am 1999; 13: 879-900.
  5. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351: 228-230.
  6. Mahe A, Simon F, Coulibaly S. Predictive value of seborrheic dermatitis and other common dermatoses for HIV infection in Bamako. Mali J Am Acad Dermatol 1996; 34: 1084-1086.
  7. Greenspan SJ, Greenspan D. Oral disease in human immunodeficiency infection, In: De Vita TV, Hellman S, Rosenberg AS, eds. AIDS: Biology, Diagnosis, Treatment and Prevention, 4th edn. Philadelphia, Lippincott-Raven Publishers, 1997: 355-361.
  8. Safai B. Noninfectious organ-specific complications of HIV infection, In: De Vita TV, Hellman S, Rosenberg AS, eds. AIDS: Biology, Diagnosis, Treatment and Prevention, 4th edn. Philadelphia, Lippincott-Raven Publishers, 1997: 393-402.
  9. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351: 256-261.
  10. Patton LL, McKaig R, Strauss R. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299-304.
  11. Itin PH, Schaub N. The impact of HAART on dermatological manifestations in HIV-positive patients. J Eur Acad Dermatol 2000; 14: 23.
  12. Detels R, Tarwater P, Phair PJ. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15: 347-355.
  13. Arribas RJ, Hernandez-Albujar S, Gonzalez-Garcia JJ. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 2000; 14: 979-985.
  14. Hoegl L, Thoma-Greber E, Rocken M. HIV protease inhibitors influence the prevalence of oral candidiasis in HIV-infected patients: a 2-year study. Mycoses 1998; 41: 321-325.
  15. Cauda R, Tacconelli E, Tumbarello M. Role of protease inhibitors in preventing recurrent oral candidiasis in patients with HIV infection: a prospective case-control study. J AIDS 1999; 21: 20-25.
  16. Diz Dios P, Ocampo A, Miralles C. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87: 437-441. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on HAART 53 r 2004 British HIV Association HIV Medicine (2004) 5, 50-54 14681293, 2004, 1, · DOI
  17. Goldstein B, Berman B, Sukenik E. Correlation of skin disorders with CD4 lymphocyte counts in patients with HIV/AIDS. J Am Acad Dermatol 1997; 36: 262-264.
  18. Ceballos-Salobrena A, Gaitan-Cepeda LA, Ceballos-Garcia L. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patients Care STDs 2000; 14: 627-635.
  19. Powderly WG, Landay A, Laderman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998; 280: 72-77.
  20. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15: 2251-2257.
  21. Phair JPP, Mellors JW, Detels R. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002; 16: 2455-2459.
  22. I Dunic et al. r 2004 British HIV Association HIV Medicine (2004) 5, 50-54 14681293, 2004, 1, · DOI

Cited by

Sorted by citations

Authors
Dunic, I., Vesic, S., & Jevtovic, D.
Venue
HIV Medicine
Publisher
Wiley
Published
2004-01
Volume
5
Issue
1
Pages
50-54
ISSN
  • 1464-2662 (ISSN-L)
  • 1468-1293
DOI
10.1111/j.1468-1293.2004.00185.x
OpenAlex
W2068717533
Cited by
73
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 6 · 2020: 3 · 2019: 8 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 6
FWCI
2.70
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 19 d)
Locations
  • HIV Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV/AIDS oral health manifestations
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Nail Diseases and Treatments
Keywords
oral candidiasis, seborrheic dermatitis, HIV infection, highly active antiretroviral therapy, antimicrobial therapy, immunodeficiency
MeSH terms
Adolescent, Adult, Aged, Anti-Bacterial Agents, Candidiasis, Oral, Child, Female, Humans, Male, Middle Aged, Prospective Studies, Dermatitis, Seborrheic, HIV Infections, AIDS-Related Opportunistic Infections, Antiretroviral Therapy, Highly Active

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review